.png){kind=icon}
.png){kind=icon}
Return
The management of hepatorenal syndrome–acute kidney injury (HRS-AKI): A national survey of hepatology provider practices
.png){kind=icon}
OA
AI
G
G
S
B
D
E
M
S
C
A
J
G
L
R
P
A
L
E
W
S
G
S
DOI：10.1097/HC9.0000000000000905.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Hepatorenal syndrome–acute kidney injury (HRS-AKI) is associated with high mortality in cirrhosis. Recent FDA approval of terlipressin and updated clinical guidance have expanded management options, but real-world practice patterns remain unknown.
Keywords:
cirrhosis
hepatorenal syndrome–acute kidney injury
terlipressin
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
4.6
Papers:
1.9K
Citations:
6.2K
Organization
U
Cited Papers